卡培他滨联合同步放疗治疗晚期乳腺癌的2期研究
这项前瞻性2期研究纳入32例化疗难治性晚期乳腺癌患者,评估卡培他滨联合同步放疗的疗效与安全性。三阴性乳腺癌患者预后显著差于非三阴性患者,中位OS为5.1个月对22.8个月(P=.007)。
要点
- 卡培他滨仅在放疗日给药可安全实施,需密切临床监测。
- 化疗难治性队列客观缓解率达73%,但≥3级非皮炎毒性常见。
- 三阴性乳腺癌即使获得缓解,预后仍差,中位OS仅5.1个月。
核心结论
- 卡培他滨联合同步放疗在化疗难治性晚期乳腺癌中可安全实施于放疗日,并带来令人鼓舞的缓解率。
- 三阴性乳腺癌患者即使获得缓解,结局仍差,非三阴性患者可能值得进一步研究。
研究设计与样本
- 前瞻性2期研究,2009至2012年纳入32例晚期乳腺癌患者,26例接受方案规定治疗。
- 入组包括化疗后不可手术、根治性手术后残留淋巴结、乳房切除后不可切除胸壁或淋巴结复发、或寡转移疾病。
- 前9例接受卡培他滨825 mg/m2每日两次持续给药,因毒性后续患者仅在放疗日给药。
- 放疗45 Gy后按RECIST评估缓解,并评估转化为可手术、局部区域控制及≥3级毒性。
主要发现
- 14例(53.9%)出现≥3级非皮炎毒性,其中持续给药组9例中7例发生。
- 4例不可手术患者中3例转化为可手术。
- 治疗队列1年 actuarial OS 为54%。
- 三阴性 versus 非三阴性患者中位OS为5.1个月 versus 22.8个月,1年局部区域无复发生存率为20% versus 63%(P=.007)。
临床怎么用
- 卡培他滨可在放疗日给药,但需仔细临床监测以管理毒性。
- 对化疗难治性晚期乳腺癌可考虑卡培他滨联合同步放疗,但三阴性患者获益有限。
局限性
- 研究因 interim analysis 提示无效而提前终止。
- 样本量小,随访时间中位仅12.9个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the response rate of gross chemo-refractory breast cancer treated with concurrent capecitabine (CAP) and radiation therapy in a prospective Phase II study. METHODS AND MATERIALS: Breast cancer patients with inoperable disease after chemotherapy, residual nodal disease after definitive surgical resection, unresectable chest wall or nodal recurrence after a prior mastectomy, or oligometastatic disease were eligible. Response by RECIST criteria was assessed after 45 Gy. Conversion to operable, locoregional control, and grade ≥3 toxicities were assessed. The first 9 patients received CAP 825 mg/m2 twice daily continuously. Because of toxicity, subsequent patients received CAP only on radiation days. Kaplan-Meier analysis was used to estimate overall survival (OS) and locoregional recurrence-free survival. RESULTS: From 2009 to 2012, 32 patients were accrued; 26 received protocol-specified treatment. Median follow-up was 12.9 months (interquartile range, 7.10-42.9 months). Nineteen patients (73%) had partial or complete response. Fourteen patients (53.9%) experienced grade 3 non-dermatitis toxicity (7 of 9 continuous dosing). Three of four inoperable patients converted to operable. One-year actuarial OS in the treated cohort was 54%. The trial was stopped early after interim analysis suggested futility independent of response. Treatment was deemed futile (ie, conversion to operable but M1 disease immediately postoperatively) in 9 of 10 patients with triple-negative (TN) versus 6 of 16 with non-TN disease (P=.014). Median OS and 1-year locoregional recurrence-free survival among non-TN versus TN patients was 22.8 versus 5.1 months, and 63% versus 20% (P=.007). CONCLUSIONS: Capecitabine can be safely administered on radiation days with careful clinical monitoring and was associated with encouraging response in this chemo-refractory cohort. However, patients with TN breast cancer had poor outcomes even when response was achieved. Further study in non-TN patients may be warranted.
引用
- Woodward WA, Fang P, Arriaga L, et al. A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28843370. doi:10.1016/j.ijrobp.2017.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。